At a glance
ClinicalIndex Comparison RecordN/ACompleted· 154 enrolled
Drug / intervention
NURO System PTNM Therapydevice
Likely dose
Not stated in record
Key inclusion· 4
- ✓Age ≥18 years
- ✓Diagnosed OAB with urgency urinary incontinence (UUI) and ≥3 episodes of urgency (mild, moderate, or severe) on 3-day voiding diary
- ✓UUI symptoms present for ≥3 months
- ✓No prior anticholinergic, antimuscarinic, or beta-3 agonist treatment for OAB
Key exclusion· 10
- ✕Prior treatment with anticholinergics, antimuscarinics, beta-3 agonists, botulinum toxin, sacral neuromodulation, or percutaneous tibial nerve stimulation for OAB
- ✕Primary stress incontinence or mixed incontinence with predominant stress component
- ✕Implantable pacemaker or defibrillator
- ✕Current transcutaneous electrical nerve stimulation (TENS) use in pelvic region, back, or legs
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation (PTNM) System in Patients With OAB
In Brief
A clinical study evaluating NURO System PTNM Therapy for Overactive Bladder. Completed, enrolled 154 participants across 11 sites.
Detailed Summary
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartSep 2016
Primary CompletionNov 2017
TodayJul 2026
First PostedAug 5, 2016
Enrollment StartSep 1, 2016
Primary CompletionNov 21, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.9 years ago
Interventions
NURO System PTNM Therapydevice